<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01211145</url>
  </required_header>
  <id_info>
    <org_study_id>D1220C00001</org_study_id>
    <nct_id>NCT01211145</nct_id>
  </id_info>
  <brief_title>Zomig - Treatment of Acute Migraine Headache in Adolescents</brief_title>
  <acronym>TEENZ</acronym>
  <official_title>A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of Zolmitriptan 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if Zomig速 Nasal Spray will help children (age
      12-17 years) with migraine headaches feel better. This will be done by comparing 3 different
      doses of Zomig Nasal Spray with placebo nasal spray (inactive treatment).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain-free Status at 2 Hours Post-treatment</measure>
    <time_frame>2 hours post-treatment.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain-free Status at 24 Hours Post-treatment</measure>
    <time_frame>24 hours post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache Response at 2 Hours Post-treatment</measure>
    <time_frame>2 hours post-treatment</time_frame>
    <description>Headache response is a binary response variable derived from the headache intensities recorded in the patient diary. Headache response is defined as a reduction in headache pain intensity from severe or moderate to mild or none with no use of rescue medication prior to the assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache Response at 24 Hours Post-treatment</measure>
    <time_frame>24 hours post-treatment</time_frame>
    <description>Headache response is a binary response variable derived from the headache intensities recorded in the patient diary. Headache response is defined as a reduction in headache pain intensity from severe or moderate to mild or none with no use of rescue medication prior to the assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Headache Response at 2 Hours</measure>
    <time_frame>Up to 2 hours post-treatment</time_frame>
    <description>Sustained headache response at 2 hours is a binary response variable derived from the headache intensities recorded in the patient diary. Sustained headache response is defined as a reduction in migraine headache pain intensity from severe or moderate to mild or none a 1 hr. which is then maintained (without a return to moderate or severe pain) at 2 hrs. with no use of rescue medication prior to the 2 hr. assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Rescue Medication During the First 24 Hours After Treatment</measure>
    <time_frame>24 hours post-treatment.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1653</enrollment>
  <condition>Migraine Headache</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZOMIG 0.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZOMIG 2.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZOMIG 5.0 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo nasal spray</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolmitriptan</intervention_name>
    <description>0.5 mg nasal spray</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Zomig速 Nasal Spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolmitriptan</intervention_name>
    <description>2.5 mg nasal spray</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Zomig速 Nasal Spray</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolmitriptan</intervention_name>
    <description>5.0 mg nasal spray</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Zomig速 Nasal Spray</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written informed consent by parent or legal guardian, and written assent
             provided by patient prior to any study specific procedures.

          -  Established diagnosis of migraine.

          -  History of a minimum of 2 migraine attacks (moderately or severely disabling)per
             month.

        Exclusion Criteria:

          -  Any medical condition that may put the patient at increased risk with exposure to
             zolmitriptan or that may interfere with the safety or efficacy assessments.

          -  A history of basilar, ophthalmoplegic, or hemiplegic migraine headache or any
             potentially serious neurological condition that is associated with headache.

          -  Have had an unacceptable adverse experience following previous use of any 5HT1B/1D
             agonist drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rohini Chitra</last_name>
    <role>Study Director</role>
    <affiliation>AZ Pharmaceuticals, US</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Winner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of The King's Daughters</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ocean Springs</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indiana</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spring</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Middleton</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mikkeli</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagykanizsa</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ny鱈regyh叩za</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sopron</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szeksz叩rd</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valmiera</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elblag</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novi Sad</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dolny Kubin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zvolen</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Finland</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
  </removed_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1740&amp;filename=D1220C00001_CSR_Synopsis.pdf</url>
    <description>D1220C00001 Clinical Study Report Synopsis</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1740&amp;filename=D1220C00001%20Revised%20CSP%203%20No%20Futility_Redacted.pdf</url>
    <description>D1220C00001 Revised CSP 3 Redacted</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2010</study_first_submitted>
  <study_first_submitted_qc>September 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2010</study_first_posted>
  <results_first_submitted>October 21, 2014</results_first_submitted>
  <results_first_submitted_qc>October 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 24, 2014</results_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>Headache</keyword>
  <keyword>Pain</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Adolescents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolmitriptan</mesh_term>
    <mesh_term>Oxazolidinones</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This multicenter study was conducted between 7 October 2010 and 31 October 2013.</recruitment_details>
      <pre_assignment_details>The study had a 30 day run-in period and up to a 10-week double-blind treatment period. Patients were randomized to receive ZOMIG nasal spray 0.5, 2.5, 5.0 mg, or matching placebo spray to treat a migraine headache. 1653 patients were enrolled, 798 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo to ZOMIG nasal spray</description>
        </group>
        <group group_id="P2">
          <title>ZOMIG 0.5 mg</title>
          <description>ZOMIG nasal spray</description>
        </group>
        <group group_id="P3">
          <title>ZOMIG 2.5 mg</title>
          <description>ZOMIG nasal spray</description>
        </group>
        <group group_id="P4">
          <title>ZOMIG 5 mg</title>
          <description>ZOMIG nasal spray</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="296"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="99"/>
                <participants group_id="P4" count="288"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="270">1 patient was not counted as completed or discontinued due to incomplete information (N=270-1=269).</participants>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="86"/>
                <participants group_id="P4" count="268"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Reason not specified</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study-specific withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe noncompliance to protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Eligibility criteria not fulfilled</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo to ZOMIG nasal spray</description>
        </group>
        <group group_id="B2">
          <title>ZOMIG 0.5 mg</title>
          <description>ZOMIG nasal spray</description>
        </group>
        <group group_id="B3">
          <title>ZOMIG 2.5 mg</title>
          <description>ZOMIG nasal spray</description>
        </group>
        <group group_id="B4">
          <title>ZOMIG 5 mg</title>
          <description>ZOMIG nasal spray</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="296"/>
            <count group_id="B2" value="115"/>
            <count group_id="B3" value="99"/>
            <count group_id="B4" value="288"/>
            <count group_id="B5" value="798"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>All randomized patients</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.3" spread="1.67"/>
                    <measurement group_id="B2" value="14.5" spread="1.72"/>
                    <measurement group_id="B3" value="14.6" spread="1.77"/>
                    <measurement group_id="B4" value="14.5" spread="1.67"/>
                    <measurement group_id="B5" value="14.4" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>All randomized patients</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="172"/>
                    <measurement group_id="B5" value="493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="116"/>
                    <measurement group_id="B5" value="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain-free Status at 2 Hours Post-treatment</title>
        <time_frame>2 hours post-treatment.</time_frame>
        <population>Full analysis set (last observation carried forward)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo to ZOMIG nasal spray</description>
          </group>
          <group group_id="O2">
            <title>ZOMIG 0.5 mg</title>
            <description>ZOMIG nasal spray</description>
          </group>
          <group group_id="O3">
            <title>ZOMIG 2.5 mg</title>
            <description>ZOMIG nasal spray</description>
          </group>
          <group group_id="O4">
            <title>ZOMIG 5 mg</title>
            <description>ZOMIG nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Pain-free Status at 2 Hours Post-treatment</title>
          <population>Full analysis set (last observation carried forward)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.312</p_value>
            <p_value_desc>Unadjusted</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>2.50</ci_upper_limit>
            <estimate_desc>ZOMIG 0.5 mg/Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.071</p_value>
            <p_value_desc>Unadjusted</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>3.26</ci_upper_limit>
            <estimate_desc>ZOMIG 2.5 mg/Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>Unadjusted</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.40</ci_lower_limit>
            <ci_upper_limit>3.39</ci_upper_limit>
            <estimate_desc>ZOMIG 5.0 mg/Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain-free Status at 24 Hours Post-treatment</title>
        <time_frame>24 hours post-treatment</time_frame>
        <population>Full analysis set (observed case)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo to ZOMIG nasal spray</description>
          </group>
          <group group_id="O2">
            <title>ZOMIG 0.5 mg</title>
            <description>ZOMIG nasal spray</description>
          </group>
          <group group_id="O3">
            <title>ZOMIG 2.5 mg</title>
            <description>ZOMIG nasal spray</description>
          </group>
          <group group_id="O4">
            <title>ZOMIG 5 mg</title>
            <description>ZOMIG nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Pain-free Status at 24 Hours Post-treatment</title>
          <population>Full analysis set (observed case)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.575</p_value>
            <p_value_desc>Unadjusted</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.91</ci_upper_limit>
            <estimate_desc>ZOMIG 0.5 mg/Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.032</p_value>
            <p_value_desc>Unadjusted</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>3.31</ci_upper_limit>
            <estimate_desc>ZOMIG 2.5 mg/Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.137</p_value>
            <p_value_desc>Unadjusted</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.95</ci_upper_limit>
            <estimate_desc>ZOMIG 5.0 mg/Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Headache Response at 2 Hours Post-treatment</title>
        <description>Headache response is a binary response variable derived from the headache intensities recorded in the patient diary. Headache response is defined as a reduction in headache pain intensity from severe or moderate to mild or none with no use of rescue medication prior to the assessment.</description>
        <time_frame>2 hours post-treatment</time_frame>
        <population>Full analysis set (last observation carried forward)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo to ZOMIG nasal spray</description>
          </group>
          <group group_id="O2">
            <title>ZOMIG 0.5 mg</title>
            <description>ZOMIG nasal spray</description>
          </group>
          <group group_id="O3">
            <title>ZOMIG 2.5 mg</title>
            <description>ZOMIG nasal spray</description>
          </group>
          <group group_id="O4">
            <title>ZOMIG 5 mg</title>
            <description>ZOMIG nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Headache Response at 2 Hours Post-treatment</title>
          <description>Headache response is a binary response variable derived from the headache intensities recorded in the patient diary. Headache response is defined as a reduction in headache pain intensity from severe or moderate to mild or none with no use of rescue medication prior to the assessment.</description>
          <population>Full analysis set (last observation carried forward)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.458</p_value>
            <p_value_desc>Unadjusted</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.96</ci_upper_limit>
            <estimate_desc>ZOMIG 0.5 mg/Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.021</p_value>
            <p_value_desc>Unadjusted</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>3.03</ci_upper_limit>
            <estimate_desc>ZOMIG 2.5 mg/Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.010</p_value>
            <p_value_desc>Unadjusted</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>2.32</ci_upper_limit>
            <estimate_desc>ZOMIG 5.0 mg/Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Headache Response at 24 Hours Post-treatment</title>
        <description>Headache response is a binary response variable derived from the headache intensities recorded in the patient diary. Headache response is defined as a reduction in headache pain intensity from severe or moderate to mild or none with no use of rescue medication prior to the assessment.</description>
        <time_frame>24 hours post-treatment</time_frame>
        <population>Full analysis set (observed case)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo to ZOMIG nasal spray</description>
          </group>
          <group group_id="O2">
            <title>ZOMIG 0.5 mg</title>
            <description>ZOMIG nasal spray</description>
          </group>
          <group group_id="O3">
            <title>ZOMIG 2.5 mg</title>
            <description>ZOMIG nasal spray</description>
          </group>
          <group group_id="O4">
            <title>ZOMIG 5 mg</title>
            <description>ZOMIG nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Headache Response at 24 Hours Post-treatment</title>
          <description>Headache response is a binary response variable derived from the headache intensities recorded in the patient diary. Headache response is defined as a reduction in headache pain intensity from severe or moderate to mild or none with no use of rescue medication prior to the assessment.</description>
          <population>Full analysis set (observed case)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.753</p_value>
            <p_value_desc>Unadjusted</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.84</ci_upper_limit>
            <estimate_desc>ZOMIG 0.5 mg/Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.145</p_value>
            <p_value_desc>Unadjusted</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>2.79</ci_upper_limit>
            <estimate_desc>ZOMIG 2.5 mg/Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.127</p_value>
            <p_value_desc>Unadjusted</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>2.04</ci_upper_limit>
            <estimate_desc>ZOMIG 5.0 mg/Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Headache Response at 2 Hours</title>
        <description>Sustained headache response at 2 hours is a binary response variable derived from the headache intensities recorded in the patient diary. Sustained headache response is defined as a reduction in migraine headache pain intensity from severe or moderate to mild or none a 1 hr. which is then maintained (without a return to moderate or severe pain) at 2 hrs. with no use of rescue medication prior to the 2 hr. assessment.</description>
        <time_frame>Up to 2 hours post-treatment</time_frame>
        <population>Full analysis set (observed case)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo to ZOMIG nasal spray</description>
          </group>
          <group group_id="O2">
            <title>ZOMIG 0.5 mg</title>
            <description>ZOMIG nasal spray</description>
          </group>
          <group group_id="O3">
            <title>ZOMIG 2.5 mg</title>
            <description>ZOMIG nasal spray</description>
          </group>
          <group group_id="O4">
            <title>ZOMIG 5 mg</title>
            <description>ZOMIG nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Headache Response at 2 Hours</title>
          <description>Sustained headache response at 2 hours is a binary response variable derived from the headache intensities recorded in the patient diary. Sustained headache response is defined as a reduction in migraine headache pain intensity from severe or moderate to mild or none a 1 hr. which is then maintained (without a return to moderate or severe pain) at 2 hrs. with no use of rescue medication prior to the 2 hr. assessment.</description>
          <population>Full analysis set (observed case)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="224"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.274</p_value>
            <p_value_desc>Unadjusted</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>2.32</ci_upper_limit>
            <estimate_desc>ZOMIG 0.5 mg/Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.067</p_value>
            <p_value_desc>Unadjusted</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio, log</param_type>
            <param_value>1.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>2.91</ci_upper_limit>
            <estimate_desc>ZOMIG 2.5 mg/Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.127</p_value>
            <p_value_desc>Unadjusted</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>2.08</ci_upper_limit>
            <estimate_desc>ZOMIG 5.0 mg/Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Rescue Medication During the First 24 Hours After Treatment</title>
        <time_frame>24 hours post-treatment.</time_frame>
        <population>Full analysis set (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo to ZOMIG nasal spray</description>
          </group>
          <group group_id="O2">
            <title>ZOMIG 0.5 mg</title>
            <description>ZOMIG nasal spray</description>
          </group>
          <group group_id="O3">
            <title>ZOMIG 2.5 mg</title>
            <description>ZOMIG nasal spray</description>
          </group>
          <group group_id="O4">
            <title>ZOMIG 5 mg</title>
            <description>ZOMIG nasal spray</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Rescue Medication During the First 24 Hours After Treatment</title>
          <population>Full analysis set (observed cases)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="81"/>
                <count group_id="O4" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.153</p_value>
            <p_value_desc>Unadjusted</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>ZOMIG 0.5 mg/Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.087</p_value>
            <p_value_desc>Unadjusted</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>ZOMIG 2.5 mg/Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.004</p_value>
            <p_value_desc>Unadjusted</p_value_desc>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
            <estimate_desc>ZOMIG 5.0 mg/Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety Analysis Set (Number of Patients at Risk: Placebo=253; ZOMIG 0.5 mg=92; ZOMIG 2.5 mg=81; ZOMIG 5 mg=231)</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo to ZOMIG nasal spray</description>
        </group>
        <group group_id="E2">
          <title>ZOMIG 0.5 mg</title>
          <description>ZOMIG nasal spray</description>
        </group>
        <group group_id="E3">
          <title>ZOMIG 2.5 mg</title>
          <description>ZOMIG nasal spray</description>
        </group>
        <group group_id="E4">
          <title>ZOMIG 5 mg</title>
          <description>ZOMIG nasal spray</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="253"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="92"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="81"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Oral discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Oral pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Administration related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="253"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="92"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E4" events="29" subjects_affected="29" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Bradykinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="253"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="253"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Rhinalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="253"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="231"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jamie Mullen, Medical Science Director</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>781-472-5032</phone>
      <email>jamie.mullen@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

